Medical - Devices
Compare Stocks
5 / 10Stock Comparison
VERO vs INMD vs SSKN vs LASE vs HIMS
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Devices
Industrial - Machinery
Medical - Equipment & Services
VERO vs INMD vs SSKN vs LASE vs HIMS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Devices | Medical - Devices | Industrial - Machinery | Medical - Equipment & Services |
| Market Cap | $499K | $882M | $7M | $16M | $6.63B |
| Revenue (TTM) | $59M | $375M | $31M | $7M | $2.35B |
| Net Income (TTM) | $-55M | $87M | $-11M | $-8M | $128M |
| Gross Margin | 64.4% | 77.8% | 57.8% | 31.1% | 69.7% |
| Operating Margin | -59.0% | 21.3% | -33.3% | -126.5% | 4.6% |
| Forward P/E | — | 9.6x | — | — | 51.5x |
| Total Debt | $43M | $13M | $16M | $5M | $1.12B |
| Cash & Equiv. | $4M | $303M | $7M | $534K | $229M |
VERO vs INMD vs SSKN vs LASE vs HIMS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 22 | Apr 26 | Return |
|---|---|---|---|
| Venus Concept Inc. (VERO) | 100 | 0.4 | -99.6% |
| InMode Ltd. (INMD) | 100 | 47.0 | -53.0% |
| STRATA Skin Science… (SSKN) | 100 | 3.0 | -97.0% |
| Laser Photonics Cor… (LASE) | 100 | 38.8 | -61.2% |
| Hims & Hers Health,… (HIMS) | 100 | 372.2 | +272.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VERO vs INMD vs SSKN vs LASE vs HIMS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
VERO plays a supporting role in this comparison — it may shine differently against other peers.
INMD carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.04
- Lower volatility, beta 1.04, Low D/E 1.9%, current ratio 9.88x
- Beta 1.04, current ratio 9.88x
- Lower P/E (9.6x vs 51.5x)
SSKN lags the leaders in this set but could rank higher in a more targeted comparison.
Among these 5 stocks, LASE doesn't own a clear edge in any measured category.
HIMS is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
- 161.9% 10Y total return vs INMD's 105.0%
- 59.0% revenue growth vs VERO's -15.1%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 59.0% revenue growth vs VERO's -15.1% | |
| Value | Lower P/E (9.6x vs 51.5x) | |
| Quality / Margins | 23.3% margin vs LASE's -105.4% | |
| Stability / Safety | Beta 1.04 vs HIMS's 2.40, lower leverage | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | -2.1% vs SSKN's -93.3% | |
| Efficiency (ROA) | 11.8% ROA vs VERO's -88.6%, ROIC 13.5% vs -39.8% |
VERO vs INMD vs SSKN vs LASE vs HIMS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
VERO vs INMD vs SSKN vs LASE vs HIMS — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
INMD leads in 3 of 6 categories
HIMS leads 1 • VERO leads 0 • SSKN leads 0 • LASE leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
INMD leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HIMS is the larger business by revenue, generating $2.3B annually — 328.8x LASE's $7M. INMD is the more profitable business, keeping 23.3% of every revenue dollar as net income compared to LASE's -105.4%. On growth, HIMS holds the edge at +28.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $59M | $375M | $31M | $7M | $2.3B |
| EBITDAEarnings before interest/tax | -$31M | $81M | -$5M | -$8M | $164M |
| Net IncomeAfter-tax profit | -$55M | $87M | -$11M | -$8M | $128M |
| Free Cash FlowCash after capex | -$21M | $91M | -$4M | -$4M | $73M |
| Gross MarginGross profit ÷ Revenue | +64.4% | +77.8% | +57.8% | +31.1% | +69.7% |
| Operating MarginEBIT ÷ Revenue | -59.0% | +21.3% | -33.3% | -126.5% | +4.6% |
| Net MarginNet income ÷ Revenue | -92.8% | +23.3% | -35.6% | -105.4% | +5.5% |
| FCF MarginFCF ÷ Revenue | -35.2% | +24.2% | -11.3% | -58.7% | +3.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -8.2% | +5.3% | -21.2% | +28.3% | +28.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -8.5% | -30.8% | -5.9% | -7.4% | -27.3% |
Valuation Metrics
INMD leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 9.7x trailing earnings, INMD trades at a 81% valuation discount to HIMS's 50.3x P/E. On an enterprise value basis, INMD's 6.9x EV/EBITDA is more attractive than HIMS's 42.7x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $498,989 | $882M | $7M | $16M | $6.6B |
| Enterprise ValueMkt cap + debt − cash | $39M | $593M | $16M | $21M | $7.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | 9.73x | -0.67x | -3.29x | 50.32x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 9.64x | — | — | 51.51x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.98x | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 6.88x | — | — | 42.68x |
| Price / SalesMarket cap ÷ Revenue | 0.01x | 2.38x | 0.20x | 4.70x | 2.82x |
| Price / BookPrice ÷ Book value/share | 0.07x | 1.33x | 1.34x | 0.90x | 12.25x |
| Price / FCFMarket cap ÷ FCF | — | 10.46x | — | — | 89.61x |
Profitability & Efficiency
INMD leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
HIMS delivers a 23.7% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-17 for VERO. INMD carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to VERO's 15.16x. On the Piotroski fundamental quality scale (0–9), VERO scores 5/9 vs LASE's 1/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -17.4% | +13.3% | -8.4% | -183.5% | +23.7% |
| ROA (TTM)Return on assets | -88.6% | +11.8% | -35.9% | -43.1% | +6.0% |
| ROICReturn on invested capital | -39.8% | +13.5% | -38.9% | -42.1% | +10.7% |
| ROCEReturn on capital employed | -54.2% | +12.1% | -36.0% | -45.9% | +10.9% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 3 | 4 | 1 | 4 |
| Debt / EquityFinancial leverage | 15.16x | 0.02x | 3.31x | 0.49x | 2.07x |
| Net DebtTotal debt minus cash | $39M | -$289M | $9M | $4M | $892M |
| Cash & Equiv.Liquid assets | $4M | $303M | $7M | $533,871 | $229M |
| Total DebtShort + long-term debt | $43M | $13M | $16M | $5M | $1.1B |
| Interest CoverageEBIT ÷ Interest expense | -9.69x | — | -4.63x | -6.60x | — |
Total Returns (Dividends Reinvested)
HIMS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HIMS five years ago would be worth $23,764 today (with dividends reinvested), compared to $9 for VERO. Over the past 12 months, INMD leads with a -2.1% total return vs SSKN's -93.3%. The 3-year compound annual growth rate (CAGR) favors HIMS at 29.4% vs VERO's -79.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -82.3% | -5.9% | -86.2% | -63.8% | -23.2% |
| 1-Year ReturnPast 12 months | -88.5% | -2.1% | -93.3% | -74.1% | -51.0% |
| 3-Year ReturnCumulative with dividends | -99.1% | -60.2% | -98.3% | -76.6% | +116.6% |
| 5-Year ReturnCumulative with dividends | -99.9% | -63.9% | -98.9% | -72.0% | +137.6% |
| 10-Year ReturnCumulative with dividends | -100.0% | +105.0% | -99.6% | -72.0% | +161.9% |
| CAGR (3Y)Annualised 3-year return | -79.4% | -26.4% | -74.5% | -38.4% | +29.4% |
Risk & Volatility
Evenly matched — INMD and SSKN each lead in 1 of 2 comparable metrics.
Risk & Volatility
SSKN is the less volatile stock with a -0.24 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INMD currently trades 83.2% from its 52-week high vs VERO's 2.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.43x | 1.04x | -0.24x | 1.68x | 2.40x |
| 52-Week HighHighest price in past year | $12.93 | $16.74 | $3.86 | $6.77 | $70.43 |
| 52-Week LowLowest price in past year | $0.26 | $12.72 | $0.11 | $0.38 | $13.74 |
| % of 52W HighCurrent price vs 52-week peak | +2.1% | +83.2% | +4.5% | +10.7% | +36.4% |
| RSI (14)Momentum oscillator 0–100 | 42.9 | 39.8 | 41.6 | 38.5 | 54.5 |
| Avg Volume (50D)Average daily shares traded | 9K | 804K | 14K | 1.9M | 34.9M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: INMD as "Buy", HIMS as "Hold". Consensus price targets imply 15.6% upside for HIMS (target: $30) vs 14.9% for INMD (target: $16).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | — | — | Hold |
| Price TargetConsensus 12-month target | — | $16.00 | — | — | $29.67 |
| # AnalystsCovering analysts | — | 11 | — | — | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | 2 | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +14.5% | 0.0% | 0.0% | +1.4% |
INMD leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). HIMS leads in 1 (Total Returns). 1 tied.
VERO vs INMD vs SSKN vs LASE vs HIMS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is VERO or INMD or SSKN or LASE or HIMS a better buy right now?
For growth investors, Hims & Hers Health, Inc.
(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -15. 1% for Venus Concept Inc. (VERO). InMode Ltd. (INMD) offers the better valuation at 9. 7x trailing P/E (9. 6x forward), making it the more compelling value choice. Analysts rate InMode Ltd. (INMD) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — VERO or INMD or SSKN or LASE or HIMS?
On trailing P/E, InMode Ltd.
(INMD) is the cheapest at 9. 7x versus Hims & Hers Health, Inc. at 50. 3x. On forward P/E, InMode Ltd. is actually cheaper at 9. 6x.
03Which is the better long-term investment — VERO or INMD or SSKN or LASE or HIMS?
Over the past 5 years, Hims & Hers Health, Inc.
(HIMS) delivered a total return of +137. 6%, compared to -99. 9% for Venus Concept Inc. (VERO). Over 10 years, the gap is even starker: HIMS returned +161. 9% versus VERO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — VERO or INMD or SSKN or LASE or HIMS?
By beta (market sensitivity over 5 years), STRATA Skin Sciences, Inc.
(SSKN) is the lower-risk stock at -0. 24β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately -1084% more volatile than SSKN relative to the S&P 500. On balance sheet safety, InMode Ltd. (INMD) carries a lower debt/equity ratio of 2% versus 15% for Venus Concept Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — VERO or INMD or SSKN or LASE or HIMS?
By revenue growth (latest reported year), Hims & Hers Health, Inc.
(HIMS) is pulling ahead at 59. 0% versus -15. 1% for Venus Concept Inc. (VERO). On earnings-per-share growth, the picture is similar: Laser Photonics Corporation grew EPS 40. 5% year-over-year, compared to -869. 0% for Venus Concept Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — VERO or INMD or SSKN or LASE or HIMS?
InMode Ltd.
(INMD) is the more profitable company, earning 25. 3% net margin versus -73. 8% for Laser Photonics Corporation — meaning it keeps 25. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INMD leads at 23. 0% versus -189. 3% for LASE. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is VERO or INMD or SSKN or LASE or HIMS more undervalued right now?
On forward earnings alone, InMode Ltd.
(INMD) trades at 9. 6x forward P/E versus 51. 5x for Hims & Hers Health, Inc. — 41. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HIMS: 15. 6% to $29. 67.
08Which pays a better dividend — VERO or INMD or SSKN or LASE or HIMS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is VERO or INMD or SSKN or LASE or HIMS better for a retirement portfolio?
For long-horizon retirement investors, STRATA Skin Sciences, Inc.
(SSKN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 24)). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SSKN: -99. 6%, HIMS: +161. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between VERO and INMD and SSKN and LASE and HIMS?
These companies operate in different sectors (VERO (Healthcare) and INMD (Healthcare) and SSKN (Healthcare) and LASE (Industrials) and HIMS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: VERO is a small-cap quality compounder stock; INMD is a small-cap deep-value stock; SSKN is a small-cap quality compounder stock; LASE is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.